Topic Highlight
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 28, 2007; 13(28): 3806-3815
Published online Jul 28, 2007. doi: 10.3748/wjg.v13.i28.3806
Table 1 Common chemotherapy regimens for metastatic colorectal cancer
RegimenDescription Cycle length
5FU Mayo[93,94]5-FU 425 mg/m2/d D1-54 wk
LV 20 mg/m2/d D 1-5
5FU Roswell Park[45]5-FU 500 mg/m2/d weekly × 68 wk
LV 500 mg/m2/d weekly × 6
LVFU2[95]5FU 400 mg/m2 bolus D1 and D22 wk
(de Gramont)LV 200 mg/m2 D1 and D2
5FU 600 mg/m2 CIVI 22 h D1 and D2
LV5FU2 (AIO)[96]LV 500 mg/m2 D1 weekly × 68 wk
5FU 2300-2600 mg/m2 CIVI 24 h D1 weekly × 6
Capecitabine[48]1250 mg/m2 BD, D1-143 wk
FOLFOX4[53]Oxaliplatin 85 mg/m2 D12 wk
LV 200 mg/m2 D1 and D2
5FU 400 mg/m2 D1 and D2
5FU 600 mg/m2 CIVI 22 h D1 and D2
FOLFOX6[97]Oxaliplatin 100 mg/m2 D12 wk
LV 400 mg/m2 D1
5FU 400 mg/m2 D1
5FU 2400-3000 mg/m2 CIVI 46 h (D1, D2)
bFOL[98]Oxaliplatin 85 mg/m2 D1, D154 wk
LV 20 mg/m2 D1, D8, D15
5FU 500 mg/m2 D1, D8, D15
FUFOX[99]Oxaliplatin 85 mg/m2 D1, 15, 29;8 wk
LV 20 mg/m2 D1, 8, 15, 22, 29;
5FU 500 mg/m2 D 1, 8, 15, 22, 29
FLOX[100]Oxaliplatin 85 mg/m2 D1 wk 1, 3, 58 wk
5FU 500 mg/m2 bolus weekly wk 1-6
LV 500 mg/m2 bolus weekly wk 1-6
FOLFIRI[63]Irinotecan 180 mg/m2 D1,2 wk
LV 200 mg/m2 D1 and D2,
5FU 400 mg/m2 bolus D1 and D2,
5FU 600 mg/m2 CIVI 22h D1 and D2
IFL[62]Irinotecan 100-125 mg/m2 weekly × 4 wk6 wk
LV 20 mg/m2 weekly × 4 wk,
5FU 400-500 mg/m2 bolus weekly × 4 wk
XELOX[54]Oxaliplatin 130 mg/m2 D13 wk
Capecitabine 1 g/m2 BD D1-14
CAPOX[55]Capecitabine 1 g/m2 BD D1-143 wk
Oxaliplatin 70 mg/m2 D1, D8
XELIRI[64]Irinotecan 200-250 mg/m2 D13 wk
Capecitabine 1 g/m2 BD D1-14
CAPIRI[65]Capecitabine 1 g/m2 BD D1-143 wk
Irinotecan 100 mg/m2 D1, D8
FOLFOXIRI [91,101]Irinotecan 125-175 mg/m2 D12 wk
Oxaliplatin 85-100 mg/m2 D1
LV 200 mg/m2 D1
5FU 400 mg/m2 bolus D1
5FU 3200 mg/m2 CIVI 48 h
Table 2 Key phase III trials in metastatic colorectal cancer
Author/trialnArmsRR (%)TTP (mo)OS (mo)
Van Cutsem[48]602Capecitabine18.905.213.2
5FU/LV Mayo15.004.712.1
(P NA)(P = 0.65 NS)(P = 0.33 NS)
De Gramont[53]420FOLFOX450.70916.2
LV5FU222.306.214.7
(P = 0.0001)(P = 0.0003)(P = 0.12 NS)
Hochster147FOLFOX418.719.2
TREE-1[56]bFOL206.917.9
CapeOx275.917.2
(P NA)(P NA)(P NA)
Hochster213FOLFOX + bevacizumab529.926
TREE-2[56]bFOL + bevacizumab398.320.7
CapeOx + bevacizumab4610.327
(P NA)(P NA)(P NA)
Fuchs430FOLFIRI46.607.623.1
BICC-Ca[66]mIFL41.905.817.6
(P = 0.10)
CAPIRI385.518.9
(P NA)(P NA)(P = 0.19 NS)
Fuchs117FOLFIRI + bevacizumab54.409.9NR
BICC-C 2[66]mIFL + bevacizumab53.308.318.7
(P NA)(P NA)
Saltz[62]683IFL39714.8
5FU/LV (Mayo)214.312.6
(P < 0.001)(P = 0.004)(P = 0.04)
Irinotecan
Douillard[63]387FOLFIRI356.717.4
LV5FU2 (AIO)224.414.1
(P =0.005)(P < 0.001)(P = 0.031)
Tournigand[88]220FOLFIRI ≥ FOLFOX6568.521.5
GERCORFOLFOX6 ≥ FOLFIRI54820.6
(P = NS)(P = 0.26 NS)(P = 0.99 NS)
Goldberg[89]795FOLFOX4458.719.5
N9741IFL316.915
(P = 0.002)(P = 0.0014)(P = 0.0001)
IROX356.517.4
(P = 0.03)(P = 0.001)(P = 0.09 NS)
Colucci[90]360FOLFIRI31714
FOLFOX434715
(P = 0.60 NS)(P = NS)(P = 0.28 NS)
Ross[71]200Mitomycin C + infusional 5FU547.914
Infusional 5FU385.415
(P = 0.024)(P = 0.033)(P = NS)
Souglakos et al[91]283FOLFOXIRI438.421.5
FOLFIRI33.66.919.5
(P = 0.168 NS)(P = 0.17 NS)(P = 0.337 NS)
Falcone [92]244FOLFOXIRI669.822.6
FOLFIRI416.916.7
(P = 0.0002)(P = 0.0006)(P = 0.032)
Hurwitz[24]813IFL + bevacizumab44.810.620.3
IFL34.86.215.6
(P = 0.004)(P < 0.001)(P < 0.001)
Giantonio[78]822FOLFOX4 + bevacizumab227.212.9
ECOGE 3200FOLFOX494.810.8
(P < 0.0001)(P = 0.0018)
BevacizumabDiscontinued
Cunningham[81]329Cetuximab + irinotecan22.94.18.6
BOND-1Irinotecan10.81.56.9
(P = 0.007)(P < 0.001)(P = 0.48 NS)
BOND-2[102]74Cetuximab + irinotecan + bevacizumab388.5n/a
cetuximab + bevacizumab
236.9n/a
Peeters[87]463PanitumumabImproved PFSApprox 6.5 m both arms
BSC(HR 0.54 P < 0.0001)(P = NS)